Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Brentuximab Vedotin for CD30+ PTCL Unfit for Chemotherapy
NCT07074457Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Nov 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucidinostat in peripheral T-cell lymphoma (PTCL) (2 cohorts), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Complete Response Rate. Started Nov 2024; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07074457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07074457.